North America & Europe Age-related Macular Degeneration Therapeutics Market Growth Rate, Manufacturers, Market Shares Amalysis by 2027

The North America & Europe Age-related Macular Degeneration Therapeutics Market research report covers the current scenario and the growth prospects of the global North America & Europe Age-related Macular Degeneration Therapeutics industry forecast 2021 – 2027. The report enlists several important factors, starting from the basics principal to advanced market intelligence which play a vital part in strategizing. North America & Europe Age-related Macular Degeneration Therapeutics manufacturers and is a important source of guidance and direction for companies and individuals interested in the North America & Europe Age-related Macular Degeneration Therapeutics industry.

Request Here For PDF Brochure

North America & Europe Age-related Macular Degeneration Therapeutics Market, By Disease Type (Dry AMD, and Wet AMD), By Region (North America and Europe), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Drug Type (Bevacizumab (Avastin), Aflibercept (Eylea), Brolucizumab (Beovu), Ranibizumab (Lucentis), Pegaptanib (Macugen), Verteporfin (Visudyne), Supplements, and Others), and is approximated to be worth around US$ 9,958.7 million in 2020 and is expected to manifest a CAGR of 6.1% over the forecast period (2020-2027), as mentioned in a new report published by Coherent Market Insights.

Driver

Rising incidences of age-related macular degeneration are expected to propel growth of the Age-related Macular Degeneration (AMD) therapeutics market over the forecast period. As per the publication from the European Society of Retina Specialist, about 22 million citizens of most populated nations of Europe i.e., France, Germany, Italy, the U.K., and Spain, and another 34 million people from the European Union (EU) were suffering from AMD condition in 2017.

Impact of COVID-19 epidemic

Due to the national lockdowns in major regions, the medium and small-scale ophthalmology practices were totally halted with only large ophthalmology practices been active for to deal with emergency cases. This has significantly decreased the number of footfalls of ophthalmology clinics.

Although, healthcare practitioners are opting for tele-health options for diagnosing the cancer patients with social distancing measures to tackle COVID-19 epidemic, hence not compromise with the health of patients. For consultations with doctors, the patients can place online appointments. The following measures are taken by the healthcare providers to minimized the transmission of COVID-19 pandemic,

For people entering the hospitals, the screening is to be performed in suspicion of COVID-19 symptoms.

Patients are to be encouraged by the healthcare providers for scheduling their appointments through telemedicine platforms.

Hospitals will have prohibition on visitor entry with only emergency cases being diagnosed.

Browse 46 Market Data Tables and 37 Figures spread through 166 Pages and in-depth TOC on “North America & Europe Age-related Macular Degeneration Therapeutics Market”- North America & Europe Forecast to 2027, North America & Europe Age-related Macular Degeneration Therapeutics Market, By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and by Region (North America, and Europe), By Disease Type (Dry AMD, and Wet AMD), By Drug Type (Aflibercept (Eylea), Brolucizumab (Beovu), Ranibizumab (Lucentis), Pegaptanib (Macugen), Bevacizumab (Avastin), Verteporfin (Visudyne), Supplements, and Others).

The focus of the key companies on adoption of inorganic strategies such as partnerships, dealings, agreements, and collaborations to enhance the portfolio of their products and build-up their market credibility. In September 2019, the Boehringer Ingelheim had partnered with Inflammasome Therapeutics in a co-development and licensing deal which aimed for developing three therapies that focused on retinal disorders including diabetic retinopathy, diabetic macular edema (DMA), and AMD.

Key Takeaways of the North America & Europe Age-related Macular Degeneration (AMD) Therapeutics Market:

Due to the launches of AMD therapeutics by key companies, the North America and Europe Age-related Macular Degeneration (AMD) therapeutics market is expected to manifest a CAGR of 6.1% over the forecast period. In June 2016, the Intas Pharmaceuticals had launched RAZUMAB which was biologically similar to Lucentis (Ranibizumab) which is suitable for treatment of wet AMD.

Due to rise in research and development for treatment of AMD disorders by key companies, the dry AMD segment contributes the largest share in the market in 2019 considering the type of disease. In October 2019, the medical organization, LumiThera Inc., had initiated the enrolment of patients for a multi-year clinical study in the U.S., LIGHTSITE III for treating dry AMD.

According to the type of drug, the Aflibercept (Eylea) segment had contributed the largest share in the market due to accelerated research and development work by key companies in 2019. In February 2019, Bayer AG and Regeneron Pharmaceuticals, Inc., had announced the execution of two Phase III studies, PULSAR and PHOTON for evaluating the prolonged intervals of the treatment with aflibercept 8mg formulation for diagnosing wet AMD.

Major Key Players Include In North America & Europe Age-related Macular Degeneration Therapeutics Market: Novartis AG, Bayer AG, Bausch Health Companies Inc., Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche AG, Pfizer, Inc., and Valeant Pharmaceuticals International, Inc.

Buy instant copy of this research report with Flat US $ 2000 Off@ – https://www.coherentmarketinsights.com/promo/buynow/4171

Main points in North America & Europe Age-related Macular Degeneration Therapeutics Market Report Table of Content

Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 North America & Europe Age-related Macular Degeneration Therapeutics Market Size Analysis from 2021 to 2027
11.6 COVID-19 Outbreak: North America & Europe Age-related Macular Degeneration Therapeutics Industry Impact

Chapter 2 Global North America & Europe Age-related Macular Degeneration Therapeutics Competition by Types, Applications, and Top Regions and Countries
2.1 Global North America & Europe Age-related Macular Degeneration Therapeutics (Volume and Value) by Type
2.3 Global North America & Europe Age-related Macular Degeneration Therapeutics (Volume and Value) by Regions

Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis

Chapter 4 Global North America & Europe Age-related Macular Degeneration Therapeutics Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America North America & Europe Age-related Macular Degeneration Therapeutics Market Analysis
Chapter 6 East Asia North America & Europe Age-related Macular Degeneration Therapeutics Market Analysis
Chapter 7 Europe North America & Europe Age-related Macular Degeneration Therapeutics Market Analysis
Chapter 8 South Asia North America & Europe Age-related Macular Degeneration Therapeutics Market Analysis
Chapter 9 Southeast Asia North America & Europe Age-related Macular Degeneration Therapeutics Market Analysis
Chapter 10 Middle East North America & Europe Age-related Macular Degeneration Therapeutics Market Analysis
Chapter 11 Africa North America & Europe Age-related Macular Degeneration Therapeutics Market Analysis
Chapter 12 Oceania North America & Europe Age-related Macular Degeneration Therapeutics Market Analysis
Chapter 13 South America North America & Europe Age-related Macular Degeneration Therapeutics Market Analysis
Chapter 14 Company Profiles and Key Figures in North America & Europe Age-related Macular Degeneration Therapeutics Business
Chapter 15 Global North America & Europe Age-related Macular Degeneration Therapeutics Market Forecast (2021-2027)
Chapter 16 Conclusions
Research Methodology

Request for a Sample Report

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com